Cannabinoids have established themselves as therapeutic options in the treatment of pain in recent years. Nevertheless, patients can experience problems when using them, particularly with regard to tolerance. A new aqueous nanodispersion appears to be able to eliminate these problems.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Psychooncology
Communication as the key to therapy adherence
- How do weight loss interventions affect the muscles?
Reflective evaluation: do not neglect qualitative aspects
- From biomarkers to gene therapies
Getting to know ataxias
- Evidence-based therapy for psoriasis in difficult locations
IL-23 inhibition in scalp psoriasis: what’s new?
- Obesity in the family practice
Aim for realistic goals and avoid apportioning blame
- Evidence, pathophysiology and management in the light of current data
Heart failure with improved ejection fraction (HFimpEF)
- Early rheumatoid arthritis
C1M has potential as a biomarker
- Osteoporosis